Abstract: The present invention is a novel biosensor composed of mOrange2 and mCherry fluorescent proteins operably linked via a linker, which provides a distinct color change upon separation of the fluorescent proteins.
Type:
Grant
Filed:
October 12, 2007
Date of Patent:
June 5, 2012
Assignee:
The Board of Trustees of the University of Illinois
Abstract: The present invention embraces compositions and methods for establishing and maintaining stem cells and inhibiting stem cell differentiation using a selective Protein Kinase C (PKC) inhibitor.
Type:
Grant
Filed:
June 11, 2010
Date of Patent:
June 5, 2012
Assignee:
University of Kansas
Inventors:
Soumen Paul, Debasree Dutta, Soma Ray, Jeffrey Aube, Frank John Schoenen
Abstract: The present invention provides methods for treating neurological diseases and disorders. Compounds that replace or enhance the function of SMN or alleviate or reduce a phenotype of cells with low SMN protein levels are provided. Screening methods and kits for identifying such compounds also are provided.
Type:
Grant
Filed:
March 23, 2010
Date of Patent:
May 29, 2012
Assignee:
The Trustees of the University of Pennsylvania
Abstract: The present invention is a composition and method for facilitating the internalization of a therapeutic agent into a cell. Specifically, the invention relates to the use of the extracellular domain of basigin-2, cyclophilin, or anti-basigin-2 antibody or antibody fragment as a delivery moiety for internalization of a therapeutic agent.
Type:
Grant
Filed:
May 12, 2011
Date of Patent:
May 22, 2012
Assignee:
The Board of Trustees of the University of Illinois
Abstract: Method and systems for determining if one or more animals has mastitis and for monitoring animals and the quality of the milk they produce are disclosed. Systems and test assays disclosed are used to determine the quantity of proteasomes and proteins thereof, the activity of proteasome enzymes, the quantity of proteasome bound and regulating proteins, and the quantity of ubiquinated protein. Components and reagents for use in the systems and assays are also disclosed.
Type:
Grant
Filed:
October 20, 2008
Date of Patent:
May 22, 2012
Assignee:
University of Medicine and Dentistry of New Jersey
Abstract: The present invention relates to a method for identifying compounds that modulate the activity of sirtuin deacetylase protein family members. Compounds of the invention are identified by designing or screening for a compound which binds to at least one amino acid residue of the newly identified nicotinamide inhibition and base exchange site of Sir2 and testing the compound for its ability to modulate the activity of the Sir2 protein. Compositions and methods for preventing or treating diseases or disorders associated with Sir2 are also provided.
Abstract: The present invention features a method for facilitating the fermentation of a high solids composition. The method involves subjecting the high solids composition to granular starch hydrolyzing enzyme during the fermentation process to provide a steady source of glucose. Moreover, the instant method is carried out under reduced pressure to selectively remove volatile components such as ethanol and water from the fermentation vessel.
Type:
Grant
Filed:
October 9, 2009
Date of Patent:
May 8, 2012
Assignee:
The Board of Trustees of the University of Illinois
Abstract: A method for isolating human neuroepithelial precursor cells from human fetal tissue by culturing the human fetal cells in fibroblast growth factor and chick embryo extract and immunodepleting from the cultured human fetal cells any cells expressing A2B5, NG2 and eNCAM is provided. In addition, methods for transplanting these cells into an animal are provided. Animals models transplanted with these human neuroepithelial precursor cells and methods for monitoring survival, proliferation, differentiation and migration of the cells in the animal model via detection of human specific markers are also provided.
Type:
Grant
Filed:
March 1, 2009
Date of Patent:
May 1, 2012
Assignee:
University of Utah Research Foundation
Inventors:
Margot Mayer-Proschel, Mahendra S. Rao, Patrick A. Tresco, Darin J. Messina
Abstract: An isolated factor derived from the bacterium Pseudomonas aeruginosa and confirmed by proteomics to be a protein that reduces expression of ABC transmembrane proteins and active fragments and mimetics thereof are provided. Also provided is a method for inhibiting expression of ABC transmembrane proteins in cells by administering to the cells the isolated factor or protein or active fragment thereof or a mimetic thereof. Such methods are useful in the enhancing delivery of small molecule therapeutic agents to the CNS and in treating cancers, particularly multidrug resistant cancers, and secretory diarrhea. In addition, compositions, methods for identifying compositions and methods for use of compositions that inhibit suppression of ABC transmembrane protein expression or reduce epoxide hydrolase activity by this factor are provided. Such compositions and methods are useful in treatment of cystic fibrosis.
Type:
Grant
Filed:
February 25, 2010
Date of Patent:
April 10, 2012
Assignee:
Trustees of Dartmouth College
Inventors:
Bruce Stanton, George O'Toole, Jr., Agnieszka Swiateck-Urban, Daniel P. MacEachran, Sophie Moreau Marquis
Abstract: This invention relates to a method for assessing risk of prostate cancer. Specifically, it relates to utilizing both Pro108 and Prostate Specific Antigen (PSA) in combination to determine the risk of prostate cancer. In addition, it is directed to a method for assessing risk of ovarian, colon, breast or stomach cancer utilizing Pro108 or specific antibodies to Pro108. The invention provides isolated anti-prostate, ovarian, colon, breast or stomach cancer antigen (Pro108) antibodies that bind to Pro108 on a mammalian cell in vivo. The invention also encompasses compositions comprising an anti-Pro108 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Pro108 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Pro108 antibodies. The invention encompasses a method of producing the anti-Pro108 antibodies.
Type:
Grant
Filed:
October 3, 2007
Date of Patent:
April 3, 2012
Assignee:
diaDexus, Inc.
Inventors:
Iris Simon, Laura Corral, Charis Lawrenson, Nam Kim, Glenn Pilkington, Robert L. Wolfert
Abstract: The present invention relates to methods for modulating the inflammatory response of respiratory tract cells using an agent that increases ceramide levels in the cells of the respiratory tract.
Type:
Grant
Filed:
July 2, 2010
Date of Patent:
March 27, 2012
Assignee:
McGill University
Inventors:
Stan Kubow, Regina Maria Vilela, Larry Lands
Abstract: The present invention is a method for preparing a substantially pure population of endothelial progenitor cells wherein said cells express Flk-1, CD34, ?5?1 integrin fibronectin, and vWF and exhibit an adherent phenotype and methods for using the same to decrease the severity of lung injury, prevent pulmonary edema, restore endothelial barrier function, induce productive wound healing and angiogenesis, and increase survival rate in acute lung injury (ALI).
Type:
Grant
Filed:
February 27, 2008
Date of Patent:
March 20, 2012
Assignee:
The Board of Trustees of the University of Illinois
Inventors:
Kishore K. Wary, Yidan Zhao, Asrar B. Malik, You-Yang Zhao
Abstract: The present invention relates to a method for inhibiting or reversing non-enzymatic glycation of the first intermediate of a biological moiety using an ?-thiolamine. By inhibiting or reversing non-enzymatic glycation of the biological moiety, conditions such as aging and diabetic complications can be prevented or reversed.
Abstract: The present invention relates to antibodies that differentially recognize multi-dimensional conformations of A?-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLs, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid ? 1-42.
Inventors:
Paul Acton, Zhiqiang An, Andrew J. Bett, Robert Breese, Lei Chang, Elizabeth Chen Dodson, Gene Kinney, William L. Klein, Mary P. Lambert, Xiaoping Liang, Paul Shughrue, William R. Strohl, Kristen Viola
Abstract: Polynucleotides encoding a mutant human carboxylesterase enzyme and polypeptides encoded by the polynucleotides which are capable of metabolizing a prodrug and inactive metabolites thereof to active drug are provided. Compositions and methods for sensitizing cells to a prodrug agent, inhibiting cell growth, treating drug addiction, and facilitating the metabolism of an organophosphate with this enzyme are also provided. In addition, a screening assay for identification of drugs activated by this enzyme is described.
Type:
Grant
Filed:
February 4, 2011
Date of Patent:
February 28, 2012
Assignees:
St. Jude Children's Research Hospital, The University of North Carolina
Inventors:
Philip M. Potter, Monika Weirdl, Matthew R. Redinbo
Abstract: The present invention relates to compositions for destabilizing lysosomes to increase the degradation of oncogenic or aberrant proteins for the prevention or treatment of disease. Methods for identifying agents which destabilize lysosomes are also provided as are agents identified in accordance with the screening method.
Type:
Grant
Filed:
July 30, 2004
Date of Patent:
February 28, 2012
Assignee:
Trustees of Dartmouth College
Inventors:
Sutisak Kitareewan, Roger Sloboda, Ethan Dmitrovsky
Abstract: The present invention embraces a fungal strain deficient in nicotinamide riboside import and salvage and use thereof for producing nicotinamide riboside. Methods for producing nicotinamide riboside and a nicotinamide riboside-supplemented food product using the strain of the invention are also provided.
Type:
Grant
Filed:
March 26, 2009
Date of Patent:
February 14, 2012
Assignee:
Trustees of Dartmouth College
Inventors:
Charles Brenner, Peter Belenky, Katrina L. Bogan
Abstract: Using gene expression analysis, specific biomarker genes and gene products have been identified which are activated in transformed cells, but suppressed in nontransformed cells; or suppressed in transformed cells, but activated in transformed cells affected by Contact Normalization. Thus, the present invention features compositions and methods for detecting, diagnosing, treating and prognosing cancer.
Type:
Grant
Filed:
March 11, 2009
Date of Patent:
February 14, 2012
Assignee:
University of Medicine and Dentistry of New Jersey
Abstract: Methods for inhibiting cardiomyocyte apoptosis and/or to improving cardiac function and inhibiting inflammation-induced apoptosis in endothelial cells by delivering BRCA1 are provided. Such methods are useful in treatment and prevention of cardiovascular diseases.
Type:
Grant
Filed:
October 2, 2009
Date of Patent:
February 7, 2012
Assignees:
St. Michael's Hospital, King Saud University
Abstract: The present invention embraces microRNA-21 antagonists and activators of Programmed Cell Death 4 for use in decreasing glial tumor cell proliferation and treating glioma.